The use of erythropoietin to treat anemia in acute kidney injury (AKI) is controversial. No
previous clinical trial has assessed the possible reduction of transfusions when
erythropoietin is started very early in a setting of in-hospital acute kidney injury.
This randomised multicenter pragmatic clinical trial will compare the need for transfusion in
acute kidney injury between two groups: group 1 will receive erythopoietin 4000 UI every
other day and group 2 the usual treatment.